Another review that limited its meta-analysis to treatment with warfarin vs
Abstract
Evidence from trials of warfarin versus aspirin in primary care populations, which might
Adapted from McNamara et al (2004) 32
6% vs
Although the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK) study Background: Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown
N Engl J Med 2011;365:981-992
Ischemic stroke or systemic embolism
4%; the risk was lowest in patients who took aspirin or warfarin monotherapy, slightly higher for clopidogrel, and markedly higher (more than 3-fold compared with warfarin alone) for dual warfarin In the Birmingham Atrial Fibrillation Treatment of the Aged trial, 3 973 patients at least 75 years old (mean age 81
7 years, the composite outcome of fatal or disabling stroke Aims: We assessed the effect of concomitant aspirin use on the efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation (AF)
1–3 Oral anticoagulants have been shown to be more effective for stroke prevention than antiplatelet therapy with aspirin alone 4, 5 or aspirin plus clopidogrel
However, this treatment carries a risk of bleeding and the need for frequent medical monitoring
4 – 6 Many patients who do not receive VKA receive aspirin for stroke prevention
It's used to help lower fevers and relieve pain from minor injuries in people 12 years of age and older
The Stroke Prevention in Atrial Fibrillation (SPAF) I study assessed aspirin, at 325 mg a day, compared to placebo and to warfarin in patients without prior stroke who had non-valvular atrial fibrillation (NVAF)
For patients older than 80 years, the corresponding rate is approximately 10%